AmorChem, a Montréal-based venture capital fund focused on life sciences, is partnering with assistant professor Przemyslaw Sapieha from the Hôpital Maisonneuve-Rosemont and Univalor. Financial details have not been disclosed.
The partnership will focus on developing new drug therapies for the treatment of diabetic macular edema. Sapieha’s research has been focussing on Semaphorin 3A and its role in ocular diseases. The research has already led to the discovery of therapeutics which may be useful in treating and stopping the development of…
